Liquid chromatography–tandem mass spectrometry (LC–MS/MS) reveals distinct sphingolipid patterns in anorexia and obesity.
|Articles|October 24, 2016
- The Column-10-24-2016
- Volume 12
- Issue 19
Vol 12 No 19 The Column October 24, 2016 North American PDF
Click the title above to open The Column October 24, 2016 North American issue, Volume 12, Number 19, in an interactive PDF format.
Advertisement
Articles in this issue
about 10 years ago
Characterizing Pigments in Peppersabout 10 years ago
Phenomenex to be Acquired by Danaher Corporationabout 10 years ago
Identifying and Discovering Marine Lipid Biomarkers Using LOBSTAHSabout 10 years ago
Time for a Change?about 10 years ago
Quantifying TBT Contamination in Whole Water Bodiesabout 10 years ago
Assessing Permeation of VOCs Through Polymeric Materialsabout 10 years ago
Vol 12 No 19 The Column October 24, 2016 Europe and Asia PDFAdvertisement
Related to this article
Leon Niezen and Gert Desmet discuss uncertainty-driven LC method development, peak overlap, and moving from in silico to real data.
Leon Niezen and Gert Desmet describe how predictive uncertainty can make automated LC method development more reliable.
Liquid chromatography–mass spectrometry (LC–MS) serum profiling ties lysine compounds to lupus kidney disease.
Liquid chromatography-mass spectrometry (LC–MS) growth lifts Waters Q3; MOBILion ion mobility buy expands proteomics.
Liquid chromatography–tandem mass spectrometry (LC–MS/MS) measures galactose-1-phosphate in dried blood spots to monitor galactosemia.
Sam Whitmarsh explores how retention-time models handle interlaboratory data, novel chemotypes, unusual phases and ionisable compounds, and what labs need to do to build useful in-house models.
Advertisement
Advertisement
Trending on LCGC International
1
AI/ML Now: Toxicity Prediction for Unknown LC–HRMS Features Using Machine Learning
2
LCGC Blog: Building a Career Series That Goes Beyond the Surface
3
Industry Roundup: Waters Posts Strong Third Quarter as LC–MS and Chromatography Consumables Drive Growth, Acquires Ion Mobility Pioneer MOBILion
4
From 9000 Clues to a Clinical Test: Mass Spectrometry-Driven Lipidomics for Early Cancer Detection
5